Cytokinetics, Incorporated (NASDAQ:CYTK) Stock Has Average Price Target of $106.06 According to Brokerages

Key Points

• Analyst sentiment is moderately bullish: 18 of 20 brokerages rate Cytokinetics a buy, with an average 12-month price target of $106.06 versus the stock’s recent price of $61.62.
• Aficamten remains the main catalyst: Additional Phase 3 ACACIA-HCM data supported the drug’s effects, dose-adjustment strategy, and safety profile, potentially strengthening its commercial prospects in non-obstructive hypertrophic cardiomyopathy.
• Shares remain under pressure despite clinical optimism: CYTK was down 1.9%, with revenue falling 57.1% year over year in the latest quarter and the company continuing to report losses; insiders also sold $13.6 million of stock over the past three months, largely through pre-arranged trading plans.

Shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) have been given an average rating of "Moderate Buy" by the twenty brokerages that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eighteen have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $106.06.

Several equities analysts have recently weighed in on the company. Truist Financial lifted their price objective on Cytokinetics from $106.00 to $112.00 and gave the company a "buy" rating in a report on Monday, August 10th. Mizuho increased their target price on Cytokinetics from $100.00 to $118.00 and gave the stock an "outperform" rating in a research note on Wednesday, June 24th. Needham & Company LLC increased their target price on Cytokinetics from $102.00 to $112.00 and gave the stock a "buy" rating in a research note on Friday, August 7th. Citizens Jmp raised their target price on shares of Cytokinetics from $105.00 to $110.00 and gave the stock a "market outperform" rating in a report on Friday, August 7th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Cytokinetics in a research note on Friday, September 11th.

More Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Additional analyses from the Phase 3 ACACIA-HCM study further characterized aficamten’s effects across exercise-performance measures and patient responder groups. The data also supported the drug’s dose-adjustment approach and safety profile, potentially strengthening Cytokinetics’ case for aficamten as a future treatment for non-obstructive HCM. Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
• Positive Sentiment: Several market commentaries highlighted the Phase 3 aficamten results and the possibility that the drug’s multi-domain benefits could improve Cytokinetics’ long-term commercial outlook. The company’s pipeline and potential heart-drug opportunity are driving the fresh investor interest, although regulatory and commercialization risks remain. Cytokinetics Highlights Exercise Capacity, Responder Data For Aficamten in NHCM
• Neutral Sentiment: Wall Street Zen upgraded Cytokinetics to a “Hold,” suggesting a more balanced view of the shares after the recent clinical updates rather than a clearly bullish or bearish shift. Wall Street Zen Upgrades Cytokinetics to Hold
• Neutral Sentiment: Chief Executive Officer Robert I. Blum sold 7,500 shares for approximately $471,600 under a pre-arranged Rule 10b5-1 trading plan. Because the sale was scheduled in advance and he retained 278,544 shares, it is a limited signal of insider sentiment, though it may add modest pressure to investor perception. SEC Form 4 Filing

Insider Activity at Cytokinetics

In related news, EVP Fady Malik sold 3,500 shares of the business's stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $61.38, for a total value of $214,830.00. Following the sale, the executive vice president directly owned 153,902 shares of the company's stock, valued at approximately $9,446,504.76. The trade was a 2.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Robert E. Landry sold 1,000 shares of the company's stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $72.13, for a total transaction of $72,130.00. Following the completion of the transaction, the director directly owned 8,184 shares of the company's stock, valued at approximately $590,311.92. The trade was a 10.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 191,426 shares of company stock worth $13,601,885 over the last three months. 2.60% of the stock is currently owned by insiders.

Institutional Trading of Cytokinetics

Several hedge funds and other institutional investors have recently modified their holdings of CYTK. Integrated Wealth Concepts LLC acquired a new position in Cytokinetics during the second quarter worth $36,000. Rockefeller Capital Management L.P. grew its position in Cytokinetics by 842.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 641 shares of the biopharmaceutical company's stock valued at $41,000 after purchasing an additional 573 shares in the last quarter. Western Wealth Management LLC bought a new position in Cytokinetics in the first quarter valued at $53,000. EverSource Wealth Advisors LLC increased its stake in Cytokinetics by 55.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,548 shares of the biopharmaceutical company's stock valued at $102,000 after buying an additional 549 shares during the last quarter. Finally, GAMMA Investing LLC increased its stake in Cytokinetics by 12.0% in the 2nd quarter. GAMMA Investing LLC now owns 2,487 shares of the biopharmaceutical company's stock valued at $212,000 after buying an additional 266 shares during the last quarter.

Cytokinetics Trading Down 1.9%

CYTK stock opened at $61.62 on Wednesday. The business's 50-day moving average price is $71.13 and its two-hundred day moving average price is $73.27. The firm has a market cap of $7.67 billion, a PE ratio of -8.53 and a beta of 0.41. Cytokinetics has a 1-year low of $54.30 and a 1-year high of $88.31.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.63) by $0.13. The business had revenue of $28.62 million during the quarter, compared to analyst estimates of $17.59 million. During the same period in the previous year, the firm posted ($1.12) earnings per share. The firm's revenue was down 57.1% on a year-over-year basis. On average, analysts forecast that Cytokinetics will post -5.98 earnings per share for the current year.

About Cytokinetics

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that improve muscle function. The company applies muscle biology and molecular pharmacology to develop therapies for cardiovascular and neuromuscular diseases in which impaired muscle performance contributes to disease progression or disability.

Its lead programs include aficamten, a next-generation cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy, and other investigational compounds designed to modulate the activity of cardiac or skeletal muscle.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.